Table 1.
Biotechnological anti-interleukin treatments.
| Biological Drug | Mechanism of Action | FDA Approval for Psoriasis |
|---|---|---|
| Etanercept | Anti-TNFα | 2004 |
| Infliximab | Anti-TNFα | 2006 |
| Adalimumab | Anti-TNFα | 2008 |
| Certolizumab-pegol | Anti-TNFα | 2008 |
| Golimumab | Anti-TNFα | 2009 |
| Ustekinumab | Anti p40 IL-12/IL-23 | 2009 |
| Secukinumab | Anti-IL-17A | 2015 |
| Ixekizumab | Anti-IL-17A | 2016 |
| Brodalumab | Anti-IL-17RA | 2017 |
| Guselkumab | Anti-p19 IL-23 | 2017 |
| Tildrakizumab | Anti-p19 IL-23 | 2018 |
| Risankizumab | Anti-IL-23A | 2022 |
| Bimekizumab | IL-17A/F | 2023 |
Legend: FDA: Food and Drug Administration.